CV Sciences (CVSI) Company Report

The CBD Nutraceuticals Market was valued at USD 9.75 billion in 2023 and is projected to reach USD 39.06 billion by 2032, demonstrating a CAGR of 16.38% from 2024-2032.
In 2023, North America led the market with a 50% share, while Asia Pacific is anticipated to exhibit the fastest compound annual growth rate of 18.48% during the forecast period.
CBD tinctures dominated the product segment in 2023 with a 40% market share, and capsules and soft gels are expected to be the fastest-growing product segment.
CV Sciences Inc. acquired Elevated Softgels LLC in May 2024, strengthening its global presence and position in the CBD nutraceuticals industry.

Dec 6, 2025, 1:45 PM

CV Sciences, Inc. Reports Third Quarter 2025 Financial Results

CVSI

Earnings

Product Launch

Demand Weakening

CV Sciences, Inc. reported revenue of $3.3 million for the third quarter of 2025, representing a 16% decrease compared to $3.9 million in the third quarter of 2024, primarily attributed to lower sales volume due to out-of-stock issues and restrictive regulations.
The company achieved a gross margin of 48.5% for Q3 2025, an increase from 46.0% in Q3 2024, but recognized an Adjusted EBITDA loss of $118,000 for the quarter, compared to a loss of $75,000 in Q3 2024 and a positive Adjusted EBITDA of $59,000 in Q2 2025.
The cash balance at the end of Q3 2025 was $0.4 million, down from $0.5 million at the end of 2024.
CV Sciences expanded its +PlusCBD™ product offering with the launch of Ignite, a men's performance formula.
The CEO highlighted that restrictive language for the hemp industry in recent funding legislation will not go into effect for a one-year period, providing an opportunity to work on a balanced regulatory framework.

Nov 13, 2025, 9:04 PM

CV Sciences, Inc. Issues Senior Secured Note

CVSI

Debt Issuance

CV Sciences, Inc. entered into a note purchase agreement on October 6, 2025, and issued a $600,000 secured promissory note to an institutional investor, with the transaction closing on October 7, 2025.
The note included an original issuance discount of $150,000, and the company paid an additional $150,000 to the investor for modifying a previous agreement, resulting in net proceeds of $300,000.
The note has a maturity date of April 6, 2027, and requires monthly repayments of $46,153.85 starting on April 6, 2026.
This financing is secured by all of the Company's assets and its subsidiaries' assets, including intellectual property.

Oct 10, 2025, 9:05 PM

CV Sciences, Inc. Amends Secured Promissory Note Terms

CVSI

Debt Issuance

CV Sciences, Inc. entered into an agreement on September 12, 2025, to amend the terms of a $1,600,000 Secured Promissory Note with an institutional investor.
The maturity date of the Note has been extended from August 12, 2026, to February 12, 2027.
The monthly redemption schedule for the Note was revised to $106,666.67 for the first 3 months, followed by $0 for the next 6 months, and then $106,666.67 for the subsequent 12 months.
As consideration for these amendments, the company will provide the investor with $150,000 in cash.